Vismodegib
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Vismodegib: From Basal Cell Carcinoma to Medulloblastoma with Extensive Nodularity
One-Sentence Summary
Vismodegib is a Smoothened (SMO) inhibitor whose real-world approved use is for locally advanced/metastatic basal cell carcinoma (BCC) — as reflected in this evidence pack's own rank-9 candidate, which carries strong clinical trial support. The TxGNN model's top-ranked prediction, however, points to Medulloblastoma with Extensive Nodularity, a SHH-pathway-driven brain tumour. This specific prediction is currently supported by 0 clinical trials and 0 publications in this dataset — the mechanistic rationale is strong, but the evidence chain still needs to be built.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available from Norway licensing data (drug not marketed). Based on evidence-pack context (rank 9 rationale), vismodegib's known real-world approved indication is locally advanced/metastatic basal cell carcinoma (BCC) |
| Predicted New Indication | Medulloblastoma with extensive nodularity |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 |
| Norway Market Status | ✗ Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Vismodegib is a Smoothened (SMO) antagonist that blocks the Hedgehog (Hh) signaling pathway. This official MOA field is marked as a data gap in this pack, but the mechanism is consistently described across the pack's own rationale texts and cited literature (e.g., PMID 22679179, PMID 24756807): vismodegib binds SMO and prevents aberrant activation of GLI transcription factors, suppressing tumour proliferation in Hh-driven cancers.
The predicted indication — SHH-subtype medulloblastoma — is mechanistically well matched: this brain tumour subtype is directly dependent on constitutive Hedgehog pathway activation, the same pathway vismodegib was designed to block. This is analogous to vismodegib's established real-world approved use in BCC, where PTCH1/SMO pathway mutations drive tumorigenesis (see the rank-9 candidate "skin cancer" in this same pack, which shows large-scale Phase II trial support, e.g. NCT01367665, n=1232).
Notably, the rationale attached to this top-ranked prediction explicitly notes: "現實世界中 vismodegib 已核准用於成人復發性/轉移性髓母細胞瘤" (vismodegib is already approved in the real world for adult recurrent/metastatic medulloblastoma). This suggests the TxGNN model has correctly identified a mechanistically and clinically valid signal — the absence of trials/literature in this specific dataset likely reflects a gap in evidence retrieval/indexing for this exact indication term, rather than an absence of real-world evidence. This gap should be closed by targeted literature search before proceeding.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Norway Market Information
No market authorization data available — vismodegib is not currently marketed in Norway (0 authorizations on file).
Cytotoxicity
Vismodegib is an antineoplastic agent (Hedgehog pathway inhibitor used in cancer indications), so this section applies.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (Hedgehog pathway / Smoothened inhibitor) — not a conventional cytotoxic chemotherapy agent |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA/label warnings and contraindications are flagged as a Blocking data gap [DG001] in this evidence pack — this must be resolved before any S1 safety evaluation can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score for this indication is very high (99.93%), and the mechanistic rationale (SHH-pathway dependency in medulloblastoma) is sound and consistent with vismodegib's known real-world use. However, this dataset currently provides zero clinical trials and zero literature citations for this specific indication, placing it at evidence level L5 — model prediction only, with no corroborating study evidence assembled yet.
To proceed, the following is needed:
- Targeted literature/trial search for "vismodegib + medulloblastoma" (the rationale text itself indicates real-world approval exists — this needs to be sourced and added to the evidence pack)
- TFDA/product label warnings and contraindications (DG001, Blocking severity — currently prevents S1 safety evaluation)
- Formal mechanism of action (MOA) documentation from DrugBank (DG002, High severity)
- Norway market authorization pathway assessment, since the drug is currently not marketed there
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.